Daiwa Upgrades Eli Lilly to Buy Following Obesity Drug Success
Eli Lilly & Co. (NYSE: LLY) shares increased on Dec 16, 2025, after Daiwa upgraded the pharmaceutical company from a Neutral to a Buy rating. The stock reached $1,062.71 at the time of the upgrade, reflecting a 3.4% rise or $35.20 from the previous close.
Bank of America maintained a Buy rating on the stock while adjusting the price target to $1,268 from $1,286. Analyst Jason Gerberry noted room for stock upside due to the successful launch of obesity treatments. The company has experienced double-digit revenue growth driven by its leadership in injectable GLP-1 medications.
The company is preparing for the 2026 launch of Orfoglipron, an oral GLP-1 weight-loss pill. This product is expected to drive international expansion and further strengthen the position of Eli Lilly in the therapeutics market. Shares of the company have gained over 30% during the current year.
During the trading session, the stock reached a high of $1,065 and a low of $1,032.55. Over the previous 52 weeks, the share price has ranged from $623.78 to $1,111.99. The current market capitalization stands at approximately $954.62 billion with a trading volume of 3,695,377 shares.
Additional information regarding the company can be found in the LLY and the LLY. Investors can also review the LLY and the LLY for further context.
Eli Lilly and Company (LLY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.